Hansoh Pharma Licenses Preclinical Oral GLP-1R Agonist HS-10535 to Merck for $1.12M Upfront; U.S. Biosecure Act Excluded from CR Bill
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Huadong Medicine
Large Comprehensive Pharmaceutical Product Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
The GLP-1 market is becoming increasingly vibrant.
On December 18, Hansoh Pharma announced that it had licensed the global rights of the preclinical small molecule GLP-1 receptor agonist HS-10535 to Merck. The latter paid $112 million upfront, up to $1.9 billion in milestone payments, and a certain percentage of sales royalties, with the total agreement amounting to up to $2.012 billion.
The Biosecurity Act is approachingFar.
On December 18, the U.S. Congress released the draft of the 2025 Continuing Appropriations and Extensions Act (CR Act, also known as the Continuing Resolution) that may undergo deliberation. The Biosecure Act was not included, and names of relevant entities previously mentioned in the Biosecure Act, such as WuXi affiliates and MGI Tech, were also absent.
Lilly's Alzheimer's Drug Launches in the Chinese Market.
On December 18, Eli Lilly announced that the NMPA approved the marketing application for donanemab injection, used to treat mild cognitive impairment and mild dementia caused by Alzheimer's disease in adults.
The First Hong Kong Stock Innovative Drug-themed ETF with Shares Exceeding 10 Billion is Born.
As of December 17, the Hong Kong Stock Connect Innovative Drug-themed Fund, Hong Kong Stock Connect Innovative Drug ETF (513120), has seen net inflows for six consecutive trading days, with its latest share volume reaching 10.1 billion shares, hitting a record high. This also marks the first time that an innovative drug-themed ETF fund in the China market has surpassed 10 billion shares.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1）Hansoh PharmaGLP-1 Receptor Agonists Go Global
On December 18, Hansoh Pharma announced that it had licensed the global rights of the preclinical small molecule GLP-1 receptor agonist HS-10535 to Merck. The latter paid $112 million upfront, up to $1.9 billion in milestone payments, and a certain percentage of sales royalties, with the total agreement amounting to up to $2.012 billion.
/ 02 /
Capital Information
1) The First ETF with a Share Scale Exceeding 10 Billion in the Hong Kong Stock Market's Innovative Drug Sector is Born
As of December 17, the Hong Kong Stock Exchange's innovative drug-themed fund, Hong Kong Innovative Drug ETF (513120), has seen net inflows for six consecutive trading days, with its latest share volume reaching 10.1 billion shares, hitting a record high. This also makes it the first innovative drug-themed ETF fund in the Chinese market to break through 10 billion shares.
/ 02 /
Pharmaceutical News
1) Huadong Medicine HDM1005 Injection Receives FDA Approval for Clinical Trials in the United States
On December 18, the clinical trial application for HDM1005, a long-acting dual-target agonist of peptide-based human GLP-1 and GIP receptors, has been approved by the FDA, allowing the initiation of Phase I clinical trials in the United States for the treatment of heart failure with preserved ejection fraction (HFpEF) in patients with comorbid obesity.
2) Eli Lilly's Alzheimer's drug approved in China
On December 18, Eli Lilly announced that the NMPA had approved the marketing application for donanemab injection, used to treat mild cognitive impairment and mild dementia in adults caused by Alzheimer's disease.
3) ZhiKang Hongyi's SC0062 Phase 2 Clinical Study in Diabetic Nephropathy Cohort Meets Primary Endpoint
On December 18, ZhiKang HongYi announced that the diabetic nephropathy cohort study results of the Phase 2 clinical trial, named 2-SUCCEED, for the endothelin receptor A (ETA) small molecule antagonist SC0062, have reached the primary clinical endpoint at 12 weeks.
/ 03 /
Instrument Tracking
1) Beijing-Yichang Laser Q-Switched Nd:YAG Laser Treatment Machine Obtains Registration Approval
On December 18, according to the NMPA website, the Beijing-Chongqing Q-switched Nd:YAG laser therapy machine obtained registration approval.
2) Carl Zeiss Nd: YAG Ophthalmic Laser Treatment Device Obtains Registration Approval
On December 18, according to the NMPA website, Carl Zeiss Nd: YAG Ophthalmic Laser Therapeutic Equipment obtained registration approval.
3) Da'an Gene's Hereditary Deafness Gene Detection Kit (PCR-Flow Fluorescence Hybridization Method) Obtains Registration Approval
On December 18, according to the NMPA website, Da'an Gene's Hereditary Deafness Gene Detection Kit (PCR-Flow Fluorescence Hybridization Method) obtained registration approval.
4) Brainlab Neurosurgical Surgery Navigation and Positioning System Receives Registration Approval
On December 18, according to the NMPA website, the neurosurgical surgical navigation and positioning system developed by Baihui Weikang obtained registration approval.
/ 04 /
Digital Healthcare Daily
1) Huwei Intelligent Colon Polyp Electronic Lower Gastrointestinal Endoscopic Image Auxiliary Detection Software Obtains Registration Approval
On December 18, according to the NMPA website, the software for auxiliary detection of electronic lower gastrointestinal endoscopic images of intestinal polyps by Huiwei Intelligence received registration approval.
2) Yukun Network Coronary Artery Calcification Scoring Assistance Software Obtains Registration Approval
On December 18, according to the NMPA website, Yukun Network's Coronary Calcium Scoring Assistant Assessment Software received registration approval.
/ 05 /
Overseas Pharma News
1) The U.S. Biosecurity Act was not included in the CR bill.
On December 18, the U.S. Congress released the draft of the 2025 Continuing Appropriations and Extensions Act (CR Act, also known as the Continuing Resolution) that may undergo review. The Biosecure Act was not included, and names of entities previously mentioned in the Biosecure Act, such as WuXi affiliates and MGI Tech, did not appear.
2) Sanofi/Teva's TL1A Monoclonal Antibody Phase IIb Study for Inflammatory Bowel Disease Successful
On December 17, Sanofi and Teva announced that the Phase IIb RELIEVE UCCD study of TL1A monoclonal antibody duvakitug met its primary endpoint, showing higher clinical remission rates compared to placebo in the treatment exploration for patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD).
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
